Population pharmacokinetic analysis of sorafenib in patients with solid tumours

AIMS: To characterize the pharmacokinetics (PK) of sorafenib in patients with solid tumours and to evaluate the possible effects of demographic, clinical and pharmacogenetic (CYP3A4*1B, CYP3A5*3C, UGT1A9*3 and UGT1A9*5) covariates on the disposition of sorafenib. METHODS: PK were assessed in 111 pat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Jain, Lokesh, Woo, Sukyung, Gardner, Erin R, Dahut, William L, Kohn, Elise C, Kummar, Shivaani, Mould, Diane R, Giaccone, Giuseppe, Yarchoan, Robert, Venitz, Jürgen, Figg, William D
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Science Inc 2011
Matèries:
Uropharmacology Themed Section
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3162659/
https://ncbi.nlm.nih.gov/pubmed/21392074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2011.03963.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars